Casirivimab/imdevimab - Wikipedia
https://en.wikipedia.org/wiki/Casirivimab/imdevimabOn 21 November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19in people twelve years of age or older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who ha…
REGN-COV2 – Wikipedia
https://no.wikipedia.org/wiki/REGN-COV2REGN-COV2, solgt under merkenavnet Ronapreve, er et eksperimentelt legemiddel utviklet av det amerikanske bioteknologiske selskapet Regeneron Pharmaceuticals. Det er en kunstig «antistoffcocktail» som tar sikte på å utvikle motstandskraft mot koronaviruset SARS-CoV-2 som forårsaker covid-19-pandemien. Den består av en blanding av to monoklonale antistoffer, REGN10933 og REGN10987. Kombinasjonen av flere antistoffer har til hensikt å forhindre fluktm…
REGEN-COV EUA Treatment and Prophylaxis of COVID-19
https://www.regencov.com22.12.2021 · REGEN-COV is not authorized for pre-exposure prophylaxis for prevention of COVID-19. REGEN-COV has not been approved, but has been authorized for emergency use by FDA. These uses are authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under section 564 (b) (1) of the Act ...
Regeneron’s COVID-19 Response Efforts
https://www.regeneron.com/covid19Science: “REGN-COV2 Antibody Cocktail Prevents and Treats SARS-CoV-2 Infection in Rhesus Macaques and Hamsters” demonstrated the efficacy of REGEN-COV in non-human primates and hamsters, and showed its ability to reduce virus load in lower and upper airways and decrease virus-induced pathological impact.